Liquamar
Liquamar Uses, Dosage, Side Effects, Food Interaction and all others data.
Coumarin derivative that acts as a long-acting oral anticoagulant.
Liquamar, a coumarin anticoagulant, thins the blood by antagonizing vitamin K which is required for the production of clotting factors in the liver. Anticoagulants such as phenprocoumon have no direct effect on an established thrombus, nor do they reverse ischemic tissue damage (damage caused by an inadequate blood supply to an organ or part of the body). However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae.
| Trade Name | Liquamar |
| Generic | Phenprocoumon |
| Phenprocoumon Other Names | Fenprocumon, Fenprocumone, Phenprocoumarol, Phenprocoumarole, Phenprocoumon, Phenprocoumone, Phenprocoumonum, Phenprocumone |
| Type | |
| Formula | C18H16O3 |
| Weight | Average: 280.3178 Monoisotopic: 280.109944378 |
| Protein binding | 99% |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Liquamar is an anticoagulant drug used for the prevention of thrombosis.
Used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
Liquamar is also used to associated treatment for these conditions: Embolism venous, Myocardial Infarction, Thrombotic events
How Liquamar works
Liquamar inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
Toxicity
50=500 mg/kg. Symptoms of overdose includes suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries).
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
- Ensure consistent Vitamin K intake. Changes in vitamin K intake may impact coagulation.
- Exercise caution with grapefruit products.
- Exercise caution with St. John's Wort.
Elimination Route
Bioavailability is close to 100%
Half Life
5-6 days
Innovators Monograph
You find simplified version here Liquamar
